New York City, New York Oct 16, 2022 (Issuewire.com) - Patients suffering from cancers have poor survival rates and few therapeutic options--but with multiple anticancer peptides, things could change.
Anticancer peptides (ACPs) are currently found to be effective in inducing cancer cell death by tumor cell necrosis, apoptosis, or in inducing reversion of tumor cells to the untransformed phenotype. They can exert their effects on cancer cells and do not affect normal cells, bringing hope to patients struggling with cancer.
However, as more researches on peptide-based anticancer drugs proceed to the latter stages of trials or commercialization, the market is facing a significant shortage of peptide materials. Many efforts have been made to address the pressing issue. BOC Sciences, the specialist in amino acid and peptide technologies, is no exception. It has established a sub-brand AAPEP, capable of supplying over 12,000 amino acids, peptides, and resins for laboratory and scientific use.
There is a large catalog of anticancer peptides available at BOC Sciences. "I would like to highlight our immune checkpoint inhibitors, RGD peptides, gonadotropin-releasing hormone (GnRH) analogs, matrix metalloproteinase (MMP) inhibitors & substrates, growth factor (GF) analogs, and melanoma peptides," the chief researcher of BOC Sciences introduced.
Although ACPs represent a promising alternative to conventional therapies, they still have some disadvantages, including substantial toxicity and poor targeting, which seriously impair their potency. BOC Sciences scientists have devoted significant efforts to improving the mechanisms of effective reconstruction or modification of ACPs so as to enhance their therapeutic properties and reduce their toxicity.
To keep up with the market trend that customized peptides are becoming increasingly popular, BOC Sciences also developed advanced amino acids synthesis technologies that can synthesize over 2000 amino acid derivatives and meet every unique requirement of customers.
"As the purchase manager of our lab, I have to take multiple factors like stability, purity, and expenses into account to target the best peptide supplier. It's glad to find BOC Sciences matches all our requirements, and we have cooperated pleasantly for years," a regular customer of BOC Sciences commented.
Peptide-based clinical trials for different types of cancers are now proceeding smoothly and quickly. Coupled with the strong material support from BOC Sciences and its peer companies, the industry is confident to witness more revolutionary breakthroughs soon.
Please visit the BOC Sciences peptide innovation hub at https://aapep.bocsci.com/ for more information.
About
With a long-term experience in peptide manufacturing and synthesis, BOC Sciences has now gained fame in providing a series of peptides for diverse research projects, for instance, research on cancers, cardiovascular disease, diabetes, and HIV.
Media Contact
Alex Brown account@bocsci.com 6314854226 New York City, New York https://aapep.bocsci.com/
